Lutetium Lu-177 dotatate
SSTR-targeted radiopeptide
Also Lutathera, Lu-177 dotatate, 177Lu-DOTATATE, Lutetium-177 dotatate, Lu177 dotatate, 177Lu-DOTA-TATE
- Evidence
- AStrong human evidence
- FDA status
- FDA approvedas of 2026-10-26
- Route
- Intravenous
- Studies cited
- 1 human0 animal or cell
It is a radioactive drug given through a vein to treat certain gut tumors. A trial of 229 patients showed it cut the risk of the tumor growing by 79%.
Sold for
Lutathera is discussed in oncology circles, with no wellness market, as the first radioactive peptide drug to win FDA approval and the model for the targeted radioligand drugs that followed.
Studies say
A 229-patient randomized trial showed a 79 percent reduction in progression or death versus octreotide, which supports an A grade for its approved use.
Why grade A. Approval rests on NETTER-1, a randomized open-label phase 3 trial in 229 patients with progressive midgut neuroendocrine tumors, which showed a large improvement in progression-free survival over high-dose octreotide, supported by a Dutch single-center series of more than 1,200 patients. The remaining gap is overall survival, where the final NETTER-1 analysis showed no statistically significant difference. 12
FDA. Approved. Lutetium Lu-177 dotatate (Lutathera, Novartis) was approved in January 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults, and in 2024 the indication was extended to patients aged 12 and older. 2
Written from 2 cited sources. Fact-checked 2026-10-27: 16 claims checked, 3 corrected. Last refreshed 2026-10-27. Not physician reviewed.
What this means for you
- What people take it for
- Treating certain gut tumors
- Can a US doctor prescribe it?
- Yes, FDA approved for certain gut and pancreas tumors.
- Properly tested in people?
- Yes, in a controlled trial of 229 patients.
Evidence checklist
- Randomised controlled trial NETTER-1, open-label vs high-dose octreotideyes
- Human study over 100 people NETTER-1, 229; Dutch series 1,214yes
- More than one research group Pivotal trial plus one single-centre seriesno
- Clinical outcomes, not surrogate markers Progression-free survival; no clear survival gainyes
- Human safety data beyond case reports Marrow, kidney and leukemia risks documentedyes
Drawn from the cited studies below. A dash means the sources give no information.
What it is
Lutetium Lu-177 dotatate is a radiopharmaceutical. The peptide part is dotatate (DOTA-Tyr3-octreotate). It is a lab-made version of somatostatin, related to octreotide. It binds tightly to somatostatin receptor type 2. The DOTA cage holds a lutetium-177 atom. This radioactive metal gives off beta particles. Its half-life is about 6.6 days. Together they send radiation straight to cells that carry the receptor. Doctors call this peptide receptor radionuclide therapy. 2
Patients get it as an infusion into a vein at a nuclear medicine unit. An amino acid solution runs alongside it to protect the kidneys. It is approved for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These include foregut, midgut and hindgut tumors. The approval covers adults. Since 2024, it covers adolescents too. 2
How it works
Neuroendocrine tumor cells carry far more somatostatin receptor type 2 than normal tissue does. Dotatate binds the receptor. The cell pulls it in, along with the lutetium-177. The beta particles travel only about two millimeters in tissue. They damage the DNA of the tumor cell and its close neighbors. Most surrounding organs are spared. Doctors usually scan patients first with a gallium-68 or copper-64 somatostatin tracer. This confirms the tumors take up the peptide. 2
What human research shows
NETTER-1 randomized 229 patients with advanced midgut neuroendocrine tumors. Their tumors had grown on standard-dose octreotide. Patients got lutetium Lu-177 dotatate plus octreotide, or high-dose octreotide alone. At the main analysis, estimated progression-free survival at 20 months was 65.2 percent with the radioligand. It was 10.8 percent in the control arm. That is a 79 percent cut in the risk of progression or death. Response rates were 18 percent against 3 percent. 1
The label also sums up a Dutch series of 1,214 patients treated at Erasmus MC. All got the drug. It gave safety and response data across GEP-NET types. The 2024 extension to patients aged 12 and older did not rest on a separate trial of whether the drug works. The label extrapolates from NETTER-1 in adults. It adds safety, drug-level and radiation-dose data from a few adolescents. Four of them had GEP-NETs. 2
| Study | Model | Finding |
|---|---|---|
| NETTER-1 (Strosberg 2017) | Humans, n=229 with progressive midgut NETs, randomized open-label phase 3 | Progression-free survival at 20 months was 65 percent versus 11 percent on high-dose octreotide; hazard ratio 0.21. 1 |
| Lutathera prescribing information | FDA label including the Erasmus MC series (n=1,214) and pediatric pharmacokinetic and safety data | Response and safety data across GEP-NET subtypes; myelosuppression, secondary myeloid cancers, and kidney toxicity as key warnings. 2 |
Safety
Common side effects in NETTER-1 were nausea, vomiting, fatigue and low blood counts. The amino acid infusion caused some of the nausea. A minority of patients had grade 3 or 4 drops in white cells, platelets or lymphocytes. The radiation also reaches bone marrow and kidneys. So the label warns of three problems. One is bone marrow suppression. Another is secondary leukemia and myelodysplastic syndrome. About 2 percent of patients had it in long-term follow-up. The third is kidney toxicity. 12
The label also lists hormonal crisis from sudden hormone release by the tumor. It lists infertility and harm to a fetus. Patients give off radiation for days after treatment. They get instructions on limiting close contact. Researchers are still collecting kidney and marrow outcomes beyond about five years. 2
Questions for your clinician
- Does this treatment help people live longer, or mainly delay progression?
- How will my blood counts and kidney function be monitored?
- What radiation precautions apply to my family after each dose?
Questions people ask
Which patients receive lutetium Lu-177 dotatate?
Gastroenteropancreatic neuroendocrine tumors that show somatostatin receptors on imaging. It is approved for adults and patients aged 12 and older. 2
Is it chemotherapy?
No. It is a targeted radiation treatment. A somatostatin-like peptide carries a radioactive lutetium atom to the tumor cells. Beta radiation then damages them from within. 2
How well does it work?
In NETTER-1, 65 percent of patients had no progression at 20 months. On high-dose octreotide, 11 percent did. In the final overall survival analysis, 66 months after the primary analysis, the arms did not differ significantly. 12
What are the long-term risks?
Bone marrow damage and kidney injury. About 2 percent of patients got secondary leukemia or myelodysplastic syndrome. The amino acid infusion with each dose protects the kidneys. 2
Citations
- Strosberg 2017, NEJM: Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors (NETTER-1) doi.org
- Novartis: Lutathera US prescribing information novartis.com